4F-MDMB-BINACA
4F-MDMB-BINACA (also known as 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.[1] It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug. 4F-MDMB-BINACA is an agonist of the CB1 receptor, though it is unclear whether it is selective for this target.[2] In December 2019, the UNODC announced scheduling recommendations placing 4F-MDMB-BINACA into Schedule II.[3]
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C19H26FN3O3 |
| Molar mass | 363.426 |
| 3D model (JSmol) | |
| |
| |
References
- "4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework". doi:10.1111/1556-4029.14101. Cite journal requires
|journal=(help) - "4F-MDMB-BINACA(4F-MDMB-BUTINACA)" (PDF).
- "December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.